Prevalence of Persistent Severe Hypertension and Rates of Treatment Among Pregnant Patients in the Prehospital Setting.
Prehospital Emergency Care · 2026-10-30 · Observational study
Abstract
OBJECTIVES: Hypertensive disorders of pregnancy (HDP) contribute to maternal and fetal morbidity and mortality and require time-sensitive intervention. In April 2025, the American College of Obstetricians and Gynecologists (ACOG), in collaboration with the National Association of EMS Physicians (NAEMSP) and the National Association of EMTs (NAEMT), published new guidelines on the prehospital management of elevated blood pressure in pregnancy. The objective of this study was to determine the prevalence of persistent severe hypertension among pregnant patients encountered by prehospital clinicians, characterize baseline frequency of pre-guideline treatment, and establish a benchmark to inform implementation of these guidelines. METHODS: We conducted a retrospective observational cohort study using the 2024 ESO Data Collaborative public release research dataset (January 1 to December 31, 2024). We identified all 9-1-1 ground EMS scene responses for patients documented as pregnant beyond 20 weeks of gestation. We excluded injury-related encounters and patients outside the World Health Organization-defined childbearing age range (15 to 49 years). Consistent with the new guidelines, we defined persistent severe hypertension as at least two documented blood pressure measurements with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 110 mmHg. We defined guideline-adherent treatment as administration of both magnesium sulfate (MgSO4) and an antihypertensive medication (labetalol, hydralazine, or nifedipine). RESULTS: We identified 39,546 eligible 9-1-1 ground EMS scene responses for patients beyond 20 weeks of gestation. The prevalence of persistent severe hypertension was 3.1% (n = 1,234/39,546). Among these patients, 77 (6.2%) received magnesium sulfate only, 19 (1.5%) received an antihypertensive medication only, and 10 (0.8%) received guideline-adherent treatment with both magnesium sulfate and an antihypertensive medication. CONCLUSIONS: Approximately 1 in 32 pregnant patients beyond 20 weeks of gestation encountered by prehospital clinicians had persistent severe hypertension. In the year prior to dissemination of the 2025 ACOG, NAEMSP, and NAEMT-supported guidelines, fewer than 1% received guideline-adherent treatment with both magnesium sulfate and an antihypertensive medication. These findings establish a national benchmark and identify opportunities to improve prehospital care through protocol development, medication availability, clinician education, and implementation of updated guidelines.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Implementation · Magnesium · Other drugs · Pregnant patients
Related articles
- [Prehospital management of severe preeclampsia]. (Ann Fr Anesth Reanim, 2010)
- A Community Partnership Initiative in Utah to Enhance Prehospital Perinatal Care in the Prevention of Postpartum Hemorrhage. (J Midwifery Womens Health, 2026)
- Recognition and Treatment of Eclampsia on a Rural Scene Call: A Case Study of Coordinated Ground and Air Emergency Medical Services. (Air Med J, 2017)
- Early Administration of Steroids in the Ambulance Setting: An Observational Design Trial (EASI-AS-ODT). (Acad Emerg Med, 2024)
- Prehospital Care for the Adult and Pediatric Seizure Patient: Current Evidence-based Recommendations. (West J Emerg Med, 2017)
- The feasibility of task-sharing the identification, emergency treatment, and referral for women with pre-eclampsia by community health workers in India. (Reprod Health, 2018)